ResMed Inc (ASX: RMD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Resmed Inc. Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar. Market Cap $12.67 billion
P/E Ratio 39.53
Dividend Yield 0.77%
Shares Outstanding 1.46 billion
Earnings per share 0.530
Dividend per share 0.24
Year To Date Return -14.43%
Earnings Yield 2.53%
Franking N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
ResMed Inc (ASX: RMD)
Latest News
Investing Strategies
Pricing power: 2 ASX shares that can fight stagflation
Best Shares
Best ASX shares to buy in July 2022
Broker Notes
2 ASX 200 shares with enough pricing power to battle inflation: Expert
Best Shares
Broker rates these 2 top ASX 200 shares as buys in July
Healthcare Shares
Why Goldman Sachs sees 13% upside for the ResMed share price
Investing Strategies
This is what I’d do with these 3 battered ASX shares: fund manager
Healthcare Shares
Goldman names 2 ASX healthcare shares to buy
Investing Strategies
2 ASX shares to benefit from strong US dollar: expert
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 17 Aug 2016 | $0.0300 | 0.00% | Final | 22 Sep 2016 |
RMD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About ResMed Inc
Resmed Inc. (ASX: RMD) is a global healthcare company operating in the respiratory medical device space, particularly in the treatment of sleep apnoea.
The company is headquartered in San Diego, California, and develops and manufactures medical devices and cloud-based software applications that diagnose, treat and manage a number of respiratory disorders. These include sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases.
Resmed operates in more than 140 countries worldwide and has manufacturing facilities in Australia, Singapore, France, and the United States.
Resmed first listed on the ASX on 25 Nov 1999 and is now recognised as a blue chip healthcare share on the ASX 200 index.
RMD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 04 Jul 2022 | $31.34 | $0.84 | 2.75% | 1,273,422 | $31.44 | $31.62 | $31.30 |
| 01 Jul 2022 | $30.50 | $-0.19 | -0.62% | 1,406,258 | $30.73 | $30.84 | $30.33 |
| 30 Jun 2022 | $30.69 | $-0.11 | -0.36% | 799,143 | $31.00 | $31.09 | $30.69 |
| 29 Jun 2022 | $30.80 | $0.05 | 0.16% | 1,306,413 | $30.58 | $30.84 | $30.36 |
| 28 Jun 2022 | $30.75 | $-0.04 | -0.13% | 1,289,766 | $30.79 | $30.79 | $30.56 |
| 27 Jun 2022 | $30.79 | $0.34 | 1.12% | 1,634,862 | $30.61 | $30.90 | $30.40 |
| 24 Jun 2022 | $30.45 | $0.80 | 2.70% | 1,712,454 | $29.83 | $30.45 | $29.82 |
| 23 Jun 2022 | $29.65 | $0.60 | 2.07% | 1,328,639 | $29.36 | $29.66 | $29.31 |
| 22 Jun 2022 | $29.05 | $-0.10 | -0.34% | 1,336,715 | $28.96 | $29.10 | $28.88 |
| 21 Jun 2022 | $29.15 | $0.10 | 0.34% | 1,967,665 | $29.37 | $29.38 | $28.98 |
| 20 Jun 2022 | $29.05 | $0.48 | 1.68% | 1,419,903 | $28.54 | $29.05 | $28.46 |
| 17 Jun 2022 | $28.57 | $-0.27 | -0.94% | 1,759,271 | $27.84 | $28.57 | $27.83 |
| 16 Jun 2022 | $28.84 | $-0.17 | -0.59% | 1,329,064 | $28.90 | $29.12 | $28.78 |
| 15 Jun 2022 | $29.01 | $-0.74 | -2.49% | 1,839,776 | $29.23 | $29.42 | $28.95 |
| 14 Jun 2022 | $29.75 | $0.06 | 0.20% | 2,137,106 | $28.95 | $29.75 | $28.75 |
| 10 Jun 2022 | $29.69 | $0.10 | 0.34% | 1,634,213 | $29.50 | $29.93 | $29.30 |
| 09 Jun 2022 | $29.59 | $-0.12 | -0.40% | 913,883 | $29.45 | $29.76 | $29.41 |
| 08 Jun 2022 | $29.71 | $0.75 | 2.59% | 1,239,217 | $29.55 | $29.84 | $29.55 |
| 07 Jun 2022 | $28.96 | $-0.04 | -0.14% | 1,136,961 | $29.21 | $29.38 | $28.76 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Peter Craig Farrell | Non-Executive DirectorNon-Executive Chairman | Jul 2002 | Dr Farrell has over 35 years executive and consulting experience in the medical device industry. Dr Farrell is a Fellow of several professional bodies, including the Australian Academy of Technological Sciences and Engineering, and the Australian Institutes of Management and Company Directors. He is a former Chair of the Executive Council of the Division of Sleep Medicine at Harvard Medical School but still serves on their Board. He also serves on the Boards of the Rady Management and the Jacobs Engineering Schools of the University of California, San Diego (UCSD) and is also on the Health Sciences Advisory Board of UCSD' s School of Medicine. Dr Farrell is a Visiting Professor at the University of New South Wales (UNSW) and is also Chair of the UNSW Centre for Innovation and Entrepreneurship. |
| Mr Ronald R Taylor | Non-Executive Director | Jan 2005 | Mr Taylor is a director of Actavis, Inc. and Red Lion Hotels Corp. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. In 1987, Mr. Taylor founded Pyxis Corporation where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc. Before joining Hybritech, he served over 10 years in management roles at Allergan Pharmaceuticals. |
| Mr Richard Sulpizio | Non-Executive Director | Aug 2005 | Mr Sulpizio has served as president and chief executive officer of Qualcomm Enterprise Services. He currently serves as a senior advisor to Qualcomm Enterprise Services. Mr Sulpizio held various positions with Qualcomm during his 20-year tenure there, including president and chief operating officer. He served as a member of Qualcomm's board of directors from 2000 until 2007. Before joining Qualcomm, Mr Sulpizio worked for eight years at Unisys Corporation. Mr Sulpizio currently serves as a director of CA, Inc. |
| Mr Michael J Farrell | Chief Executive OfficerExecutive Director | Mar 2013 | Mr Farrell was foundation director of Biomedical Engineering at the University of New South Wales where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. Since 2005, Dr Farrell has been a director of NuVasive, Inc. He also serves as the non-executive chair of QRxPharma. |
| Ms Carol Burt | Non-Executive Director | Aug 2014 | No profile reported in Annual Report. |
| Ms Karen Ruth Drexler | Non-Executive Director | Nov 2017 | No profile reported in Annual Report. |
| Mr Jan De Witte | Non-Executive Director | May 2019 | Mr De Witte is the chief executive officer and member of the board of directors of Barco NV. |
| Ms Harjit Gill | Non-Executive Director | Nov 2018 | No profile reported in Annual Report. |
| Mr David Pendarvis | Company Secretary | - | |
| David Pendarvis | Company Secretary | - |
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| No Top 20 Shareholder Information | 0 | 0.00% |